SAMHD1 Research Digest — 2026-08-26¶
Generated by samhd1_monitor | Model: claude-sonnet-5
Summary: 4 papers evaluated | 0 high-relevance (≥7) | 4 medium (5–6) | 0 low (3–4) | 0 scored <3
🟡 Medium Relevance (Score 5–6)¶
Score ≥6 auto-added to Zotero; lower scores: review manually
Emerging microbiome-mitochondria crosstalk in host defense and infectious diseases: mechanistic insights into NLRP3 inflammasome activation and mtDNA-mediated immunomodulation. (from Gastroenterology/microbiome-infectious disease)
Lu Xinxing; Sun Wenbin; Zhang Daowei; Hou Bin; Tai Huiyu — Frontiers in cellular and infection microbiology 2026
Score: 6/10 | Pathways: NLRP3, cGAS-STING, mito-ROS-NF-kB, treatment-target
Reviews gut-microbiome-mtDNA-NLRP3/cGAS-STING crosstalk mechanistically parallel to the ox-mtDNA/NLRP3 and mitophagy pathways central to the SAMHD1 interferon-mitochondrial model, though not SAMHD1-specific.
DOI: 10.3389/fcimb.2026.1866924
Dysregulation of the KLF9/TXNRD2 Axis Leads to Mitochondrial DNA Oxidation and NLRP3 Inflammasome Activation in Ulcerative Colitis. (from gastroenterology)
Fan Yijia; Dai Lingling; Zhu Feng; Ping Mingfang; Zhu Xiaofeng — Journal of biochemical and molecular toxicology 2026
Score: 6/10 | Pathways: NLRP3, POLG-mtDNA, clinical-phenotype
Demonstrates ox-mtDNA release triggering NLRP3 inflammasome activation via a KLF9/TXNRD2 oxidative stress axis, mechanistically parallel to the PURPLE/GOLD ox-mtDNA-NLRP3 pathway though in a UC epithelial context rather than SAMHD1-driven interferonopathy.
DOI: 10.1002/jbt.71074
Dihydroquercetin alleviates mitochondrial dysfunction and inhibits NLRP3-mediated pyroptosis in primary hepatocytes from chronic liver failure patients. (from Hepatology/pharmacology)
Ao Shen; Pengxiang Wang; Bing Wu; Hong Fu; Yuqiao Zeng — American journal of translational research 2026
Score: 6/10 | Pathways: NLRP3, treatment-target, mito-ROS-NF-kB
Demonstrates NLRP3/caspase-1/IL-1β pyroptotic axis driven by mitochondrial dysfunction (ox-mtDNA release, JC-1 depolarization) in hepatocytes, directly paralleling the family's PURPLE/GOLD loop mechanism and hepatic steatosis phenotype, with a candidate therapeutic (DHQ) targeting the same NLRP3-mitochondrial node.
DOI: 10.62347/ifrp1860
The private truncating Toll-like receptor 7 p.Glu834* variant associates with juvenile-onset systemic lupus erythematosus and pathological cytokine expression in vitro. (from Rheumatology/pediatric lupus genetics)
Y. Renaudineau; J. Hawkes; Katarzyna Mizgalska; V. Natoli; J. Roachdown — Annals of the rheumatic diseases 2026
Score: 5/10 | Pathways: JAK-STAT, AGS-spectrum, clinical-phenotype, treatment-target
Describes a distinct monogenic type I interferonopathy (TLR7 gain-of-function) causing lupus via enhanced IFN signaling, mechanistically analogous but not directly linked to the SAMHD1-driven interferon-mitochondrial axis.
DOI: 10.1016/j.ard.2026.07.024
Pathway Coverage This Week¶
NLRP3: 3 paperstreatment-target: 3 papersmito-ROS-NF-kB: 2 papersclinical-phenotype: 2 paperscGAS-STING: 1 papersPOLG-mtDNA: 1 papersJAK-STAT: 1 papersAGS-spectrum: 1 papers